Kraematon Investment Advisors’s Merck MRK Stock Holding History

Kraematon Investment Advisors’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-883	Closed	-$98K	–	181
2022 Q4	$98K	Buy	+883	New	+$90.3K	0.11%	105

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kraematon Investment Advisors's MRK Position: Q1 2023 in Review

Kraematon Investment Advisors sold out of Merck (MRK) in Q1 2023, closing a stake of 883 shares — an estimated $98K sold.

Kraematon Investment Advisors first reported a position in MRK in Q4 2022 and held it in 1 quarter. The position peaked at $98K in Q4 2022. 3,180 funds tracked by Wall St. Rank hold MRK as of Q1 2023.

Kraematon Investment Advisors reported no remaining Merck position as of Q1 2023 after selling out during the quarter.
Kraematon Investment Advisors sold 883 Merck shares in Q1 2023, an estimated $98K.
Kraematon Investment Advisors first reported a position in Merck in Q4 2022 and held it in 1 quarter.
Kraematon Investment Advisors's Merck position peaked at $98K in Q4 2022.
3,180 funds tracked by Wall St. Rank held Merck as of Q1 2023.

Based on Kraematon Investment Advisors's 13F filing for Q1 2023, filed 13 Apr 2023.